Uncategorized – Page 270

AbbVie’s Rinvoq Leads Immunology Market as Physicians Rank Players, J&J Sees Decline

1 year ago talkbio0Tagged AbbVie, Approved, Crohn 's disease, Drops - Drug Form, Humira, Immunology, Inhibitor, J&J, Janus kinase, Physicians ' ranking, Players, Rinvoq, United States Food and Drug Administration

AbbVie, Rinvoq, Immunology players, Physicians’ ranking, J&J drop, Humira, Crohn’s disease, FDA approval, JAK inhibitor

Landmark Federal Data Privacy Proposal Unveiled

1 year ago talkbio0Tagged Consumer, federal, Privacy, proposal - intent, public showcase, rights, Rules of conduct

Federal Data Privacy, Public Showcase, Proposal, Consumer Rights, Privacy Law

Sanofi Restructures US Commercial Vaccine Group Amid Cost-Saving Campaign

1 year ago talkbio0Tagged Commercial Vaccine, Cost-Savings Campaign, Effectiveness, Efficiency, Employee, Evolving, Market, Optimization, Outplacement, restructuring, sanofi, streamlined strategic sales, Structure, Vaccines

Sanofi, Restructuring, US Commercial Vaccine Group, Cost-Savings Campaign, Streamlined Strategic Sales Structure, Evolving Vaccine Market, Optimization for Efficiency and Effectiveness, Employee Support and Outplacement Assistance

Vertex’s Acquisition of Alpine Immune Sciences for Povetacicept: Humira-like Potential in IgAN, but Indication Variations Matter

1 year ago talkbio0Tagged ALPN-303, Humira-like potential, IGA Glomerulonephritis, multiple autoimmune diseases, Povetacicept

Vertex, Alpine Immune Sciences, Povetacicept (ALPN-303), IgA nephropathy (IgAN), Humira-like potential, Multiple autoimmune diseases

Biopharma Layoff Tracker 2024: Sanofi, Vedanta, Fujifilm, and More Companies Reduce Workforce

1 year ago talkbio0Tagged Acorda, Biological Factors, Biopharma layoffs, Cara, Eiger, Fujifilm, Genomic Orientation, Invitae, Pfizer, sanofi, Vedanta

Biopharma layoffs, Sanofi, Vedanta, Fujifilm, Acorda Therapeutics, Eiger BioPharmaceuticals, Invitae, Sientra, Strand Therapeutics, Cara Therapeutics, Pfizer

Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC

1 year ago talkbio0Tagged Alecensa, ALINA, ALK gene, ALK Positive, Approved, Cessation of life, disease recurrence, Early-stage, genentech, Guidelines, Immunologic Adjuvants, Inhibitor, NCCN, Non-Small Cell Lung Carcinoma, Roche (company), United States Food and Drug Administration

Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines